<strong>Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes Mellitus</strong>
Martin Schön(Deutsches Diabetes-Zentrum e.V.), the GDS group, Iryna Yurchenko(Deutsches Diabetes-Zentrum e.V.), Róbert Wágner(Deutsches Diabetes-Zentrum e.V.), Michael Roden(Düsseldorf University Hospital), Maximilian Huttasch(Deutsches Diabetes-Zentrum e.V.), Clara Möser(Deutsches Diabetes-Zentrum e.V.), Maria Bombrich(Deutsches Diabetes-Zentrum e.V.), Klaus Straßburger(Deutsches Diabetes-Zentrum e.V.), Geronimo Heilmann(University of Duisburg-Essen), Oana‐Patricia Zaharia(Düsseldorf University Hospital), Volker Burkart(Deutsches Diabetes-Zentrum e.V.), Vera B. Schrauwen‐Hinderling(Maastricht University Medical Centre), Gidon J. Bönhof(Heinrich Heine University Düsseldorf), Filippo Michelotti(Deutsches Diabetes-Zentrum e.V.), Yuliya Kupriyanova(Deutsches Diabetes-Zentrum e.V.), Alexander Strom(Deutsches Diabetes-Zentrum e.V.), Kálmán Bódis(Düsseldorf University Hospital), Malte Kelm(Düsseldorf University Hospital)
Cited by 0
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
The integrative biology of type 2 diabetes
|Nature|2019|1.1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789